Lantern Pharma Inc. - Common Stock (NQ:LTRN)

2.711 -0.109 (-3.88%)

Streaming Delayed Price Updated: 9:56 AM EST, Mar 2, 2026 Add to My Watchlist

Price and Volume

Volume	13,853
Open	2.790
Bid (Size)	2.700 (200)
Ask (Size)	2.810 (100)
Prev. Close	2.820
Today's Range	2.710 - 2.828
52wk Range	2.450 - 5.744
Shares Outstanding	11,184,423
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) to Present AI-Driven Neuro-Oncology Strategy at Glioblastoma Summit

February 10, 2026

Via Investor Brand Network

Lantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026

February 10, 2026

From Lantern Pharma Inc.

Via Business Wire

Performance

YTD	-12.8%	-12.8%
1 Month	-13.9%	-13.9%
3 Month	-22.8%	-22.8%
6 Month	-32.7%	-32.7%
1 Year	-26.9%	-26.9%

More News

BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) Receives FDA Orphan Drug Designation For LP-284 In Soft Tissue Sarcomas

January 20, 2026

Via Investor Brand Network

Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas

January 20, 2026

From Lantern Pharma Inc.

Via Business Wire

AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Establishes AI Center of Excellence and Advanced Agentic Labs in India

January 12, 2026

Via Investor Brand Network

Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RADR® Platform and Accelerate Global Development Opportunities with BioPharma Companies

January 12, 2026

From Lantern Pharma Inc.

Via Business Wire

New to The Street Show #710 Airs Tonight at 6:30 PM EST on Bloomberg Television

December 27, 2025

Via ACCESS Newswire

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Details Encouraging LP-184 Phase 1a Results Showing Durable Disease Control in Advanced Solid Tumors

December 03, 2025

Via Investor Brand Network

Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials

December 03, 2025

From Lantern Pharma Inc.

Via Business Wire

InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Q3 2025 Results and Highlights AI-Driven Clinical Progress

November 13, 2025

Via Investor Brand Network

Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates

November 13, 2025

From Lantern Pharma Inc.

Via Business Wire

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

November 13, 2025

Via Benzinga

Lantern Pharma Earnings Preview ↗

November 12, 2025

Via Benzinga

AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) CEO Discusses AI-Driven Cancer Drug Development in FintechTV Interview at NYSE

November 10, 2025

Via Investor Brand Network

New to The Street to Broadcast Show Number 698 on Bloomberg - Saturday, November 8, 2025, at 6:30 PM EST

November 08, 2025

Via ACCESS Newswire

Lantern Pharma Engages New to The Street for National Media Coverage Featuring Television, Press, Earned Media and Non-Deal Investor Focused Roadshows

November 07, 2025

Via ACCESS Newswire

AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Sets Nov. 13 Webcast to Review Q3 2025 Results and AI Platform Developments

November 06, 2025

Via Investor Brand Network

Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET

November 06, 2025

From Lantern Pharma Inc.

Via Business Wire

Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT

October 30, 2025

From Lantern Pharma Inc.

Via Business Wire

AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Complete Metabolic Response in Phase 1 LP-284 Trial at LL&M Congress

October 28, 2025

Via Investor Brand Network

Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers.

October 28, 2025

From Lantern Pharma Inc.

Via Business Wire

InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) to Present at ThinkEquity Conference on Oct. 30

October 24, 2025

Via Investor Brand Network

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025

October 24, 2025

From Lantern Pharma Inc.

Via Business Wire

BioMedNewsBreaks — Lantern Pharma Inc. (NASDAQ: LTRN) Advancing Drug Discovery with PredictBBB.ai(TM) Partnership

October 22, 2025

Via Investor Brand Network

MissionIRNewsBreaks – RADR(R) Platform Powers Lantern Pharma Inc.’s (NASDAQ: LTRN) Push Into Rare Pediatric Brain Cancer Treatment

October 14, 2025

Via Investor Brand Network

Frequently Asked Questions

Is Lantern Pharma Inc. - Common Stock publicly traded?

Yes, Lantern Pharma Inc. - Common Stock is publicly traded.

What exchange does Lantern Pharma Inc. - Common Stock trade on?

Lantern Pharma Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Lantern Pharma Inc. - Common Stock?

The ticker symbol for Lantern Pharma Inc. - Common Stock is LTRN on the Nasdaq Stock Market

What is the current price of Lantern Pharma Inc. - Common Stock?

The current price of Lantern Pharma Inc. - Common Stock is 2.711

When was Lantern Pharma Inc. - Common Stock last traded?

The last trade of Lantern Pharma Inc. - Common Stock was at 03/02/26 09:56 AM ET

What is the market capitalization of Lantern Pharma Inc. - Common Stock?

The market capitalization of Lantern Pharma Inc. - Common Stock is 30.32M

How many shares of Lantern Pharma Inc. - Common Stock are outstanding?

Lantern Pharma Inc. - Common Stock has 30M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.